$0.91
0.64% yesterday
Nasdaq, Oct 17, 10:00 pm CET
ISIN
US64131A1051
Symbol
STIM

Neuronetics, Inc. Stock price

$0.91
-0.04 4.40% 1M
-3.05 77.02% 6M
-1.99 68.62% YTD
-0.24 20.87% 1Y
-4.13 81.94% 3Y
-8.15 89.96% 5Y
-26.87 96.72% 10Y
Nasdaq, Closing price Thu, Oct 17 2024
-0.01 0.64%
ISIN
US64131A1051
Symbol
STIM

Key metrics

Market capitalization $27.58m
Enterprise Value $46.87m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.65
P/S ratio (TTM) P/S ratio 0.38
P/B ratio (TTM) P/B ratio 1.41
Revenue growth (TTM) Revenue growth 6.22%
Revenue (TTM) Revenue $72.07m
EBIT (operating result TTM) EBIT $-28.66m
Free Cash Flow (TTM) Free Cash Flow $-27.40m
Cash position $43.33m
EPS (TTM) EPS $-1.10
P/E forward negative
P/S forward 0.35
EV/Sales forward 0.60
Short interest 1.98%
Show more

Is Neuronetics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,907 stocks worldwide.

Neuronetics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Neuronetics, Inc. forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Neuronetics, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Neuronetics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
72 72
6% 6%
100%
- Direct Costs 21 21
15% 15%
30%
51 51
3% 3%
70%
- Selling and Administrative Expenses 68 68
0% 0%
95%
- Research and Development Expense 8.95 8.95
16% 16%
12%
-27 -27
11% 11%
-37%
- Depreciation and Amortization 2.12 2.12
6% 6%
3%
EBIT (Operating Income) EBIT -29 -29
10% 10%
-40%
Net Profit -32 -32
4% 4%
-45%

In millions USD.

Don't miss a Thing! We will send you all news about Neuronetics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neuronetics, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
Data selected for oral presentation reinforce previous findings on safety and efficacy Data selected for oral presentation reinforce previous findings on safety and efficacy
Neutral
PRNewsWire
14 days ago
MALVERN, Pa. and TORONTO , Oct. 4, 2024 /PRNewswire/ - Neuronetics, Inc. (NASDAQ: STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTCMKTS: GBNHF) ("Greenbrook") today announced that the Ontario Superior Court of Justice (Commercial List) (the "Court") has granted an interim order (the "Interim Order") in connection with the previously announced statutory plan of arrangement under section 182 of ...
Neutral
GlobeNewsWire
23 days ago
Policy update increases access for millions covered by HCSC BlueCross BlueShield policies Policy update increases access for millions covered by HCSC BlueCross BlueShield policies
More Neuronetics, Inc. News

Company Profile

Neuronetics, Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.

Head office United States
CEO Keith Sullivan
Employees 203
Founded 1998
Website www.neurostar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today